Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleRadiochemistry

Synthesis of the PET Tracer 124I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring

Edwin C. Pratt, Elizabeth Isaac, Evan P. Stater, Guangbin Yang, Ouathek Ouerfelli, Nagavarakishore Pillarsetty and Jan Grimm
Journal of Nuclear Medicine December 2020, 61 (12) 1845-1850; DOI: https://doi.org/10.2967/jnumed.120.241901
Edwin C. Pratt
1Department of Pharmacology, Weill Cornell Graduate School, New York, New York
2Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Isaac
1Department of Pharmacology, Weill Cornell Graduate School, New York, New York
2Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evan P. Stater
1Department of Pharmacology, Weill Cornell Graduate School, New York, New York
2Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guangbin Yang
3Organic Synthesis Core, Memorial Sloan Kettering Cancer Center, New York, New York; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ouathek Ouerfelli
3Organic Synthesis Core, Memorial Sloan Kettering Cancer Center, New York, New York; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nagavarakishore Pillarsetty
2Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Grimm
1Department of Pharmacology, Weill Cornell Graduate School, New York, New York
2Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 12 1845-1850
DOI 
https://doi.org/10.2967/jnumed.120.241901
PubMed 
32444378

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication January 23, 2020
  • Accepted for publication April 16, 2020
  • Published online December 1, 2020.

Article Versions

  • previous version (May 22, 2020 - 14:43).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Edwin C. Pratt1,2,
  2. Elizabeth Isaac1,2,
  3. Evan P. Stater1,2,
  4. Guangbin Yang3,
  5. Ouathek Ouerfelli3,
  6. Nagavarakishore Pillarsetty2,4 and
  7. Jan Grimm1,2,4
  1. 1Department of Pharmacology, Weill Cornell Graduate School, New York, New York
  2. 2Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
  3. 3Organic Synthesis Core, Memorial Sloan Kettering Cancer Center, New York, New York; and
  4. 4Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
  1. For correspondence or reprints contact: Jan Grimm, Memorial Sloan Kettering Cancer Center, 1275 York Ave., Box 248, New York, NY 10021. E-mail: grimmj{at}mskcc.org
View Full Text

Statistics from Altmetric.com

Cited By...

  • 9 Citations
  • 10 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Simultaneous quantitative imaging of two PET radiotracers via the detection of positron–electron annihilation and prompt gamma emissions
    Edwin C. Pratt, Alejandro Lopez-Montes, Alessia Volpe, Michael J. Crowley, Lukas M. Carter, Vivek Mittal, Nagavarakishore Pillarsetty, Vladimir Ponomarev, Jose M. Udías, Jan Grimm, Joaquin L. Herraiz
    Nature Biomedical Engineering 2023 7 8
  • Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma
    Laetitia Vercellino, Dorine de Jong, Laurent Dercle, Benoit Hosten, Brian Braumuller, Jeeban Paul Das, Aileen Deng, Antoine Moya-Plana, Camry A’Keen, Randy Yeh, Pascal Merlet, Barouyr Baroudjian, Mary M. Salvatore, Kathleen M. Capaccione
    Diagnostics 2022 12 5
  • Diagnostic Utility of Radiomics in Thyroid and Head and Neck Cancers
    Maryam Gul, Kimberley-Jane C. Bonjoc, David Gorlin, Chi Wah Wong, Amirah Salem, Vincent La, Aleksandr Filippov, Abbas Chaudhry, Muhammad H. Imam, Ammar A. Chaudhry
    Frontiers in Oncology 2021 11
  • Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy
    Thomas S. C. Ng, Huiyu Hu, Stefan Kronister, Chanseo Lee, Ran Li, Luca Gerosa, Sylwia A. Stopka, Danielle M. Burgenske, Ishaan Khurana, Michael S. Regan, Sreeram Vallabhaneni, Niharika Putta, Ella Scott, Dylan Matvey, Anita Giobbie-Hurder, Rainer H. Kohler, Jann N. Sarkaria, Sareh Parangi, Peter K. Sorger, Nathalie Y. R. Agar, Heather A. Jacene, Ryan J. Sullivan, Elizabeth Buchbinder, Hannes Mikula, Ralph Weissleder, Miles A. Miller
    Science Advances 2022 8 17
  • Virtual screening, molecular docking, MD simulation studies, DFT calculations, ADMET, and drug likeness of Diaza-adamantane as potential MAPKERK inhibitors
    Davood Gheidari, Morteza Mehrdad, Foroozan Hoseini
    Frontiers in Pharmacology 2024 15
  • Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition
    Patricia M.R. Pereira, Jalen Norfleet, Jason S. Lewis, Freddy E. Escorcia
    Journal of Nuclear Medicine 2021 62 3
  • Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1
    Kavita Y. Sarin, Mark Bradshaw, Chris O'Mara, Jahanbanoo Shahryari, John Kincaid, Steven Kempers, John H. Tu, Sunil Dhawan, Janet DuBois, David Wilson, Patrice Horwath, Mark P. de Souza, Christopher Powala, Gerd G. Kochendoerfer, Scott R. Plotkin, Guy F. Webster, Lu Q. Le
    Science Advances 2024 10 18
  • Cinobufagin Enhances the Sensitivity of Cisplatin‐Resistant Lung Cancer Cells to Chemotherapy by Inhibiting the PI3K/AKT and MAPK/ERK Pathways
    Guangxin Zhang, Kun Zhang, Xin Li, Xiuwen Wang, Guangquan Li, Yicun Wang
    Journal of Cellular and Molecular Medicine 2025 29 6
  • Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy
    Rohini Karunakaran, Ravindra Kumar Chourasiya, Ankur Vaidya, Ravichandran Veerasamy
    2024
  • Longitudinal multi-tracer imaging of hepatocellular carcinoma identifies novel stage- and oncogene-specific changes
    Mari Teuter, Yuhai Hu, Tobias L. Ross, Kelsey Lolatte, Michael Ott, Frank M. Bengel, Asha Balakrishnan, Jens P. Bankstahl
    Nuclear Medicine and Biology 2025 144-145

Article usage

Article usage: May 2020 to April 2025

AbstractFullPdf
May 2020255028
Jun 2020265025
Jul 202010406
Aug 202099015
Sep 2020116026
Oct 202099014
Nov 202080025
Dec 20206744481
Jan 20212181424
Feb 20211641218
Mar 20211661322
Apr 2021158826
May 2021135832
Jun 2021576957
Jul 2021275443
Aug 2021235154
Sep 2021316140
Oct 2021225360
Nov 2021214154
Dec 2021285543
Jan 2022254428
Feb 2022173727
Mar 2022225551
Apr 2022255950
May 2022247137
Jun 2022145321
Jul 2022125229
Aug 2022146834
Sep 2022133940
Oct 2022163938
Nov 2022275423
Dec 2022193836
Jan 2023176433
Feb 2023113633
Mar 2023215135
Apr 2023103620
May 2023124328
Jun 2023125024
Jul 202356320
Aug 2023284324
Sep 202394721
Oct 20231012522
Nov 20231730525
Dec 2023126223
Jan 2024145329
Feb 202494723
Mar 2024119276
Apr 2024173834
May 2024147026
Jun 2024113317
Jul 202483729
Aug 2024214640
Sep 2024165132
Oct 2024133827
Nov 2024125523
Dec 2024105023
Jan 2025134620
Feb 20251611131
Mar 20251312138
Apr 202587560
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (12)
Journal of Nuclear Medicine
Vol. 61, Issue 12
December 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Synthesis of the PET Tracer 124I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Synthesis of the PET Tracer 124I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring
Edwin C. Pratt, Elizabeth Isaac, Evan P. Stater, Guangbin Yang, Ouathek Ouerfelli, Nagavarakishore Pillarsetty, Jan Grimm
Journal of Nuclear Medicine Dec 2020, 61 (12) 1845-1850; DOI: 10.2967/jnumed.120.241901

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Synthesis of the PET Tracer 124I-Trametinib for MAPK/ERK Kinase Distribution and Resistance Monitoring
Edwin C. Pratt, Elizabeth Isaac, Evan P. Stater, Guangbin Yang, Ouathek Ouerfelli, Nagavarakishore Pillarsetty, Jan Grimm
Journal of Nuclear Medicine Dec 2020, 61 (12) 1845-1850; DOI: 10.2967/jnumed.120.241901
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Radiochemistry

  • Cyclotron-Produced 132La as a PET Imaging Surrogate for Therapeutic 225Ac
  • Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets
Show more Radiochemistry

Basic

  • Cyclotron-Produced 132La as a PET Imaging Surrogate for Therapeutic 225Ac
  • Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets
  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
Show more Basic

Similar Articles

Keywords

  • trametinib
  • small-molecular inhibitor
  • melanoma
  • MEK
  • radiochemistry
  • oncology
SNMMI

© 2025 SNMMI

Powered by HighWire